BioRx and BioDx: Can the Two Businesses Mix?
Executive Summary
Few biotech companies venture into diagnostics, largely because they believe that therapeutics and diagnostics don’t mix. However, a handful of biotech/ small pharmaceutical companies are active in diagnostics and therapeutics, taking largely one of two approaches: using diagnostics to obtain near-term cash flow or as an integral part of a broader strategy in disease management.
You may also be interested in...
Do Dx-Life Science Synergies Exist? Beckman Says 'You Bet They Do'
Life sciences and clinical diagnostics seem to have a lot in common, but their customer needs, margins and product life cycles differ significantly. Beckman Coulter, one of the few large diagnostics companies with significant life science commitments, argues vociferously in favor of the strategic value of leveraging both businesses, despite many difficulties. Its MHC tetramer program is a prime example of its strategy.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.